

**Community Pharmacy Communication Update**


**Tuesday 2<sup>nd</sup> April 2024**



THE CPD TEAM WISH ALL OUR COMMUNITY PHARMACIES AND STAFF CELEBRATING A HAPPY VAISAKHI - CPD ਟੀਮ ਸਾਡੇ ਕਮਿਊਨਿਟੀ ਫਾਰਮੇਸੀ ਨੈਟਵਰਕ ਦੇ ਸਾਰੇ ਮੈਂਬਰਾਂ ਨੂੰ ਵਿਸਾਖੀ ਦੀਆਂ ਵਧਾਈਆਂ ਦਿੰਦੀ ਹੈ  
THE CPD TEAM WISH ALL OUR COMMUNITY PHARMACIES AND STAFF CELEBRATING A HAPPY EID  
- CPD ਟੀਮ ਹਮਾਰੇ ਕਮਿਊਨਿਟੀ ਫਾਰਮਿਸੀ ਨੈੱਟ ਵਰਕ ਦੇ ਟਮਾਮ ਮਮਬਰਾਨ ਕੋ ਏਦ ਮਬਾਰਕ ਪਿਸ਼ ਕਰਤੀ ਏ-

In this edition –

- **Electronic Workbook (ECW)**
- **Important Information: Change Of Process – Submission Of PGD Authorisation Sheets**
- **PCA (P)(2024) 03 - Serious Shortage Protocol: isosorbide mononitrate (Monomil®xl) 60mg modified release tablet**
- **Updated PGDs – National Pharmacy First**
- **Fiasp FlexTouch Shortage**

ACTION	Electronic Claiming Workbook (ECW)
 ECW - V2.xlsx  Attached	<p>The Electronic Claiming Workbook (ECW) has been updated and amended to reflect the following:</p> <ul style="list-style-type: none"> <li>- Increase in fees resulting from the 5% uplift agreed between CP GGC and CPDT;</li> <li>- Changes to COPD claim form; and</li> <li>- Updated contractor details.</li> </ul> <p>The new version of the ECW is V2. You can access this from the front page of our website <a href="#">here</a> and a copy is attached.</p> <p>It is important that you submit the new version of the Workbook to ensure the correct fee is applied for the claim. Claims submitted on previous versions will be returned.</p> <p>As has become standard practice ECW's submitted with incomplete information or missing documentation will also be returned to the contractor unprocessed. Please note that the Community Pharmacy Development Team (CPDT) are unable to monitor the resubmission of such claims.</p> <p>Thank you for your continued co-operation with this process.</p> <p>Janine Glen 02/04/2024</p>

ACTION	Important Information: Change Of Process – Submission Of PGD Authorisation Sheets
	<p>As you will be aware, the Community Pharmacy Development Team (CPDT) has for many years required community pharmacists to submit a copy of their signed authorisation sheet for each PGD in existence in GGC. As part of this process the Team generates an acknowledgement to the pharmacist so that they have a record of submission.</p>

This has become somewhat of a “cottage industry” over the last few years, with the increase in the number of PGDs being used and now forms a significant element of the Team’s workload.

A recent review of the process showed that over the last 18 months, CPDT has logged information and generated acknowledgements for over 9,000 authorisation sheets. In time terms this equates to one member of staff spending one full day per week (7.5 hours) on this task.

Pharmacists are covered under the PGD as soon as they accept the professional obligations by signing the authorisation sheet. There is no regulatory or legal requirement for copies of the signed sheets to be submitted to the Board. The only requirement is that the Board (in the form of the CPDT) should keep a list of the pharmacists that have signed each PGD.

In a bid to improve support and release time to ensure CPDT have the capacity to absorb additional tasks which will benefit the community pharmacy network, the Team put forward a proposal to redesign the process moving towards a more automated approach. This was supported by both the Area Pharmaceutical Committee and CP GGC.

***Details of the change:***

***With effect from 1st April pharmacists have no need to submit their various signed PGDs to the CPDT.***

***Instead they should complete the electronic form [here](#), indicating which PGDs they have signed. The link can also be accessed from the front and PGD pages of the CPDT [website](#). If an e-mail address is provided, an automated message will be generated, providing the same acknowledgement of signing. Using this method will also allow the Board to fulfil its obligations to keep a list of pharmacists operating under the PGD, but is much less labour intensive for the CPDT and less onerous for the individual pharmacist.***

We understand that this change is a significant departure from a long established process and will take some time for the community pharmacy network to become used to.

You should note that if you submit a physical PGD authorisation sheet to CPDT after 1st April 2024, this/these will be returned to you, with a request to log your acceptance of the professional responsibility for each PGD via the new process.

Please note: This change in process will not affect payment for any services provided as part of the various PGDs.

Thank you for your co-operation.

Janine Glen  
Contracts Manager  
26/03/2024

<b>ACTION</b>	<b>PCA (P)(2024) 03 - Serious Shortage Protocol: isosorbide mononitrate (Monomil®xl) 60mg modified release tablet</b>
	<p>Please find below the latest NHS circular:</p> <p>PCA(P)(2024) 03 - Serious Shortage Protocol: isosorbide mononitrate (Monomil®xl) 60mg modified release tablet</p> <p><a href="http://www.publications.scot.nhs.uk/files/pca2024-p-03.pdf">www.publications.scot.nhs.uk/files/pca2024-p-03.pdf</a></p>

02/04/2024

**ACTION**

**Updated PGDs – National Pharmacy First**



V2 - PGD NHS PFS  
Aciclovir 800mg - As:



V2 - PGD NHS PFS  
Aciclovir 800mg.pdf



V2 - PGD NHS PFS  
Flucloxacillin - Asses



V2 - PGD NHS PFS  
Flucloxacillin.pdf



01 - Single  
Signature Sheet.doc

Attached

SG have recently published Circular: <https://www.publications.scot.nhs.uk/files/pca2024-p-02.pdf> which gives details of updated PGDs to be implemented for the treatment of shingles and skin conditions under NHS Pharmacy First Scotland.

The circular is provided for information only. Please do not sign the PGDs within the circular. Copies which have been approved through NHS GGC's local process are attached and can be accessed [here](#).

**Please note: These will be the first PGDs which will be subject to the new signing process (above).**

**From 1<sup>st</sup> April there is no need to submit your signed copy of any PGDs. Please follow the process described above to record your signing.**

Alan Harrison  
Lead Pharmacist – Community Care  
26/03/2024

**ACTION**

**Fiasp FlexTouch Shortage**



Attachments.pdf

Attachments

Fiasp® FlexTouch® (Insulin aspart) 100units/ml prefilled pens will be unavailable from April 2024 until January 2025.

Fiasp® FlexTouch® (Insulin aspart) 100units/ml solution for injection 3ml cartridges remain available to be used with reusable pens: Novopen®6 and Novopen Echo® Plus and can support increased demand.

**The shortage will only affect patients using the prefilled pens.** Patients will be contacted in April by the pharmacy teams in the practice and advised of the change. Most patients will be switched to Fiasp® 100units/ml Penfill® cartridges. Patients will be issued with a prescription for the cartridges and 2 x Novopen® reusable devices. If there are any issues regarding quota with Fiasp® Penfill® cartridges or the Novopen® device, Novo Nordisk has advised pharmacy team members to contact the Novo Nordisk customer care line on 0800 023 2573 and quote their alliance account number.

This change in insulin may require additional blood glucose monitoring. Some patients may need to be shown how to load and change an empty cartridge.

N.B. Fiasp® (insulin aspart) and Novorapid® (insulin aspart) are not interchangeable.

**FAQ**

***How to use Novopen®6 and Novopen Echo® Plus?***

Please see [NP6E-quick-guide-June-2021.pdf \(novonordisk.com\)](#)

Information sheets will be provided for patient use and will come with the Novopen® when dispensed.

**Is any dosage change required when switching patients to Fiasp® penfill® cartridges?**

The unit dose remains the same. No dosage change is required when switching patients from Fiasp® (insulin aspart) 100 units/ml prefilled FlexTouch® to Fiasp® (insulin aspart) penfill® 100unit/ml cartridges.

Your help with this shortage and change is much appreciated

**Communication Update Index link**

[INDEX - Community Pharmacy Communications Updates](#)

Any queries should be directed to the contact provided – where no specific contact is shown, queries should be directed to [ggc.cpdevteam@nhs.scot](mailto:ggc.cpdevteam@nhs.scot)

We are keen for any feedback you have about this Update. Please submit your comments/suggestions to: [cpdt@ggc.scot.nhs.uk](mailto:cpdt@ggc.scot.nhs.uk)